Osteal Therapeutics’ VT-X7 Receives FDA’s Breakthrough Therapy Designation for the treatment of periprosthetic joint infection of the hip and knee and completes enrollment of the pivotal APEX-2 trial
December 05, 2023 07:00 ET
|
Osteal Therapeutics
DALLAS, Dec. 05, 2023 (GLOBE NEWSWIRE) -- The U.S. Food and Drug Administration (FDA) granted Breakthrough Therapy Designation for VT-X7, Osteal Therapeutics’ (“Osteal’s”) investigational drug...
BioNTX Names Osteal Therapeutics 2023 Rising Star
September 28, 2023 07:14 ET
|
Osteal Therapeutics
President and CEO, David Thompson, will present at the upcoming iC³ Life Science Summit alongside fellow Rising Star recipients The award follows the announcement by Osteal of an oversubscribed $23M...
Osteal Therapeutics Closes $23M Series C Financing
September 21, 2023 08:23 ET
|
Osteal Therapeutics
Financing led by Asteroid Partners with new investor Gideon Strategic Partners and returning investors Johnson and Johnson Development Corp., HM Capital, Prism Ventures and Medvest Capital. Proceeds...
Osteal Therapeutics Announces First Subject Enrollment in Second Phase 2 Clinical Trial of VT-X7 Combination Product for Treatment of Periprosthetic Joint Infection
February 07, 2023 10:31 ET
|
Osteal Therapeutics
DALLAS, Feb. 07, 2023 (GLOBE NEWSWIRE) -- Osteal Therapeutics, Inc. (“Osteal”), a clinical-stage biopharmaceutical company developing a new category of combination therapies for musculoskeletal...
Osteal Therapeutics Announces Leadership Team Appointments
December 29, 2022 08:00 ET
|
Osteal Therapeutics
DALLAS, Dec. 29, 2022 (GLOBE NEWSWIRE) -- Osteal Therapeutics, Inc. (“Osteal”), a clinical-stage biopharmaceutical company developing a new category of combination products for musculoskeletal...
Osteal Therapeutics, Inc. Completes Enrollment in APEX Phase 2 Clinical Trial of VT-X7 for Periprosthetic Joint Infection
November 04, 2022 08:00 ET
|
Osteal Therapeutics
DALLAS, Nov. 04, 2022 (GLOBE NEWSWIRE) -- Osteal Therapeutics, Inc. (“Osteal”), a clinical-stage biopharmaceutical company developing a new category of combination therapies for musculoskeletal...
Osteal Therapeutics Closes an Oversubscribed $30 Million Series B Financing to Advance Platform Therapy for Treatment of Musculoskeletal Infection
March 08, 2022 08:50 ET
|
Osteal Therapeutics
Series B financing led by HM Capital and joined by returning investors JJDC and Medvest Capital Proceeds will support clinical development of lead candidate, VT-X7 for periprosthetic joint infection....